厄达替尼胆管癌怎么用药？厄达替尼用药注意事项看这里

Cholangiocarcinoma is a rare cancer that forms in the bile ducts. Patients with cholangiocarcinoma are usually diagnosed at an advanced or advanced stage when the prognosis is poor, with an overall median survival time of less than 12 months and a very high degree of malignancy. Activating fusion, rearrangement, translocation and gene amplification of FGFRs are closely related to the occurrence of various cancers. FGFR2 fusion is highly common in cholangiocarcinoma, with an incidence rate of 10%-16%. It is one of the most suitable targets for developing target drugs. FGFR (fibroblast growth factor receptor) is a protein on cells that helps them grow and divide. Some bladder cancer patients have changes in genes that tell cells to produce FGFR, which can help cancer cells grow. (Erdafitinib) works by targeting cells with these genetic changes. How to use erdafitinib for cholangiocarcinoma? What are the precautions for taking erdafitinib?

Erdafitinib usage and dosage

Initially 8 mg PO once daily; increase to 9 mg PO once daily based on serum phosphate (PO4) levels and tolerability over days 14-21. If serum phosphate levels are <5.5 mg/dL and there are no eye disorders or grade ≥2 adverse reactions, increase dose to 9 mg once daily. Treatment with erdafitinib was continued until disease progression or unacceptable toxicity.

Erdafitinib treatment effect

For Erdafitinib (Erdafitinib), another phase I clinical trial that included 187 patients with advanced solid tumors is also worthy of attention: 26 patients with bladder cancer had an effective rate of 46.2%; the median time of maintenance of the effect was 5.6 months; 11 patients with cholangiocarcinoma received Erdafitinib (Balversa), the effective rate was 27.3%, and the median time of maintenance of the effect was 11.4 months.

Precautions for Erdafitinib (Balversa)

Embryo-fetal toxicity: Animal experiments show that erdafitinib (Balversa) has embryo-fetal toxicity. Patients and partners should use effective contraception while taking the drug and within one month after stopping the drug.

Eye diseases: Erdafitinib (Balversa) can cause central serous retinopathy or retinal pigment epithelial detachment, with clinical symptoms such as blurred vision, visual floaters, or visual fatigue. Patients should be aware of this.

The above is the introduction about erdafitinib (Balversa), I hope it can help everyone.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: